Literature DB >> 22000002

PD-L2 is predominantly expressed by Th2 cells.

W Joost Lesterhuis, Henry Steer, Richard A Lake.   

Abstract

In response to a recently published article by Messal et al. (2011) in which the authors show that PD-L2 is expressed by activated T cells and ligation results in suppression of T cell proliferation and cytokine secretion, we here report that PD-L2 is differentially expressed by the diverse Th subsets, with predominant expression by Th2 cells.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22000002     DOI： 10.1016/j.molimm.2011.09.014

Source DB:  PubMed          Journal:  Mol Immunol        ISSN： 0161-5890            Impact factor:   4.407


  24 in total

1.  Invariant NKT cells increase drug-induced osteosarcoma cell death.

Authors:  S Fallarini; T Paoletti; N Orsi Battaglini; G Lombardi
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 2.  Checkpoint inhibitors in lung cancer: latest developments and clinical potential.

Authors:  Gustavo Schvartsman; Renata Ferrarotto; Erminia Massarelli
Journal:  Ther Adv Med Oncol       Date:  2016-07-26       Impact factor: 8.168

3.  Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity.

Authors:  Jerome Kerzerho; Hadi Maazi; Anneliese O Speak; Natacha Szely; Vincent Lombardi; Bryant Khoo; Stacey Geryak; Jonathan Lam; Pejman Soroosh; Jacques Van Snick; Omid Akbari
Journal:  J Allergy Clin Immunol       Date:  2012-11-20       Impact factor: 10.793

Review 4.  Emerging concepts in PD-1 checkpoint biology.

Authors:  Kristen E Pauken; James A Torchia; Apoorvi Chaudhri; Arlene H Sharpe; Gordon J Freeman
Journal:  Semin Immunol       Date:  2021-05-15       Impact factor: 11.130

Review 5.  Programmed death ligand 2 in cancer-induced immune suppression.

Authors:  Esdy N Rozali; Stanleyson V Hato; Bruce W Robinson; Richard A Lake; W Joost Lesterhuis
Journal:  Clin Dev Immunol       Date:  2012-04-29

6.  Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.

Authors:  Yu Rebecca Miao; Kaushik N Thakkar; Jin Qian; Mihalis S Kariolis; Wei Huang; Saravanan Nandagopal; Teddy Tat Chi Yang; Anh N Diep; Gerald Maxwell Cherf; Yu Xu; Eui Jung Moon; Yiren Xiao; Haizea Alemany; Tiane Li; Wenhua Yu; Bo Wei; Erinn B Rankin; Amato J Giaccia
Journal:  Clin Cancer Res       Date:  2021-05-19       Impact factor: 13.801

7.  PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.

Authors:  Li Liu; Qiangsun Zheng; Jun Lee; Zhiqiang Ma; Qiming Zhu; Zhiquan Wang
Journal:  J Cell Mol Med       Date:  2015-03-26       Impact factor: 5.310

8.  Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients.

Authors:  Miwa Noda; Takaaki Masuda; Shuhei Ito; Taro Tobo; Akihiro Kitagawa; Qingjiang Hu; Dai Shimizu; Hidetoshi Eguchi; Tsuyoshi Etoh; Shinji Ohno; Masafumi Inomata; Koshi Mimori
Journal:  Ann Surg Oncol       Date:  2020-03-21       Impact factor: 5.344

Review 9.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

10.  Significance of PD1 Alternative Splicing in Celiac Disease as a Novel Source for Diagnostic and Therapeutic Target.

Authors:  Candelaria Ponce de León; Pedro Lorite; Miguel Ángel López-Casado; Francisco Barro; Teresa Palomeque; María Isabel Torres
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.